In this issue:
Perioperative durvalumab for resectable NSCLC
Amivantamab + lazertinib in EGFRmutated advanced NSCLC
AZD3759 in EGFR-mutated NSCLC with CNS metastases
ICI-associated pneumonitis in advanced NSCLC
Platinum-doublet + anti-PD(L)-1 in KRASG12C-mutant NSCLC
Trastuzumab deruxtecan for HER2-mutant metastatic NSCLC
Chemoimmunotherapy in extensive-stage SCLC with poor performance status
Lorlatinib for ALK-positive NSCLC: EML4::ALK variants and ALK ± TP53 mutations
Platinum rechallenge as late-line therapy for advanced nonsquamous NSCLC
Features of long-term response to ICIs for advanced NSCLC
Please login below to download this issue (PDF)